We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
The World Health Organization have highlighted that dengue is becoming a growing public health concern globally, and that since the beginning of 2023 there has been a significant increase in dengue cases and deaths being reported from dengue-endemic countries:
Dengue has spread into regions previously considered to be free of dengue. Although dengue is not endemic in Europe, several European countries reported locally acquired cases of dengue. In 2023, locally acquired cases were reported in France, Italy and Spain.
For further information on cases and outbreaks, see the following information sources:
Dengue is a mosquito-borne viral infection transmitted to humans through the bite of infected Aedes mosquitoes. Dengue is commonly found in tropical and sub-tropical climates worldwide.
Aedes mosquitoes are particularly persistent and aggressive. They bite between dawn and dusk.
There are four serotypes of dengue virus which can lead to a wide variation in clinical symptoms. Most infections are asymptomatic. Some people will present with ‘flu-like’ illness, and symptoms usually self-resolve within 1-2 weeks. A small number (1-2%) of those infected will develop severe dengue and may require hospitalisation.
A new dengue vaccine Qdenga® has been licensed in the UK.
Dengue is the second most commonly identified cause of febrile illness in returning travellers; the number of cases in travellers continues to increase.